A detailed history of Mercer Global Advisors Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mercer Global Advisors Inc holds 373,752 shares of BMY stock, worth $21.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
373,752
Previous 382,148 2.2%
Holding current value
$21.6 Million
Previous $15.9 Million 21.87%
% of portfolio
0.04%
Previous 0.04%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $332,985 - $434,493
-8,396 Reduced 2.2%
373,752 $19.3 Million
Q2 2024

Aug 12, 2024

SELL
$40.25 - $52.99 $9.21 Million - $12.1 Million
-228,726 Reduced 37.44%
382,148 $15.9 Million
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $6.87 Million - $7.79 Million
143,127 Added 30.6%
610,874 $33.1 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $52,455 - $62,593
1,082 Added 0.23%
467,747 $24 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $1.03 Million - $1.15 Million
-17,802 Reduced 3.67%
466,665 $27.1 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $44,278 - $49,164
-695 Reduced 0.14%
484,467 $31 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $4.89 Million - $5.55 Million
74,427 Added 18.12%
485,162 $33.6 Million
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $7.16 Million - $8.48 Million
104,541 Added 34.14%
410,735 $29.6 Million
Q3 2022

Nov 15, 2022

BUY
$0.13 - $76.84 $4,302 - $2.54 Million
33,099 Added 12.12%
306,194 $21.8 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $2.28 Million - $2.51 Million
31,380 Added 12.98%
273,095 $21 Million
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $7.32 Million - $8.77 Million
118,989 Added 96.96%
241,715 $17.7 Million
Q4 2021

Feb 04, 2022

SELL
$53.63 - $62.52 $42,260 - $49,265
-788 Reduced 0.64%
122,726 $7.65 Million
Q3 2021

Nov 10, 2021

BUY
$59.17 - $69.31 $548,624 - $642,642
9,272 Added 8.12%
123,514 $7.31 Million
Q2 2021

Aug 10, 2021

BUY
$61.91 - $67.42 $583,192 - $635,096
9,420 Added 8.99%
114,242 $7.63 Million
Q1 2021

Aug 10, 2021

BUY
$59.34 - $66.74 $1.04 Million - $1.17 Million
17,590 Added 20.16%
104,822 $6.62 Million
Q1 2021

May 11, 2021

SELL
$59.34 - $66.74 $2.87 Million - $3.23 Million
-48,425 Reduced 35.7%
87,232 $5.51 Million
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $291,991 - $330,879
5,057 Added 3.87%
135,657 $8.42 Million
Q3 2020

Dec 10, 2020

BUY
$57.43 - $63.64 $1.23 Million - $1.36 Million
21,365 Added 19.56%
130,600 $7.87 Million
Q2 2020

Aug 10, 2020

BUY
$54.82 - $64.09 $1.16 Million - $1.35 Million
21,099 Added 23.94%
109,235 $6.42 Million
Q1 2020

May 18, 2020

BUY
$46.4 - $67.43 $1.82 Million - $2.64 Million
39,149 Added 79.92%
88,136 $4.91 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $295,998 - $386,102
6,015 Added 14.0%
48,987 $3.14 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $95,163 - $112,829
2,225 Added 5.46%
42,972 $2.18 Million
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $203,199 - $224,694
4,554 Added 12.58%
40,747 $1.85 Million
Q1 2019

Apr 23, 2019

SELL
$45.12 - $53.8 $215,763 - $257,271
-4,782 Reduced 11.67%
36,193 $1.73 Million
Q1 2019

Apr 12, 2019

BUY
$45.12 - $53.8 $1.85 Million - $2.2 Million
40,975 New
40,975 $2.13 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.